ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC

Interim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs chemotherapy in resected stage IB-IIIA NSCLC. But will early DFS results extend to overall survival?
Medscape Medical News

source https://www.medscape.com/viewarticle/997606?src=rss